Bioton set for injection into Russian insulin market

According to announcements, sales of insulin to Russia will boost the company's revenues by $20 million and within two years the company plans to seize 20% of Russia's $200-million-a-year market."Revenues from this market should grow dynamically. In October, we will take part in a large tender for sale of insulin in Russia for the following year," explained Adam Wilczega, president of Bioton. The company plans to operate globally and to this end it is already present in the Far East, Western Europe and both American continents. By the end of the year Bioton's share in the global insulin market will top 3%. In H1, the Bioton group posted a net profit of zl.15.75 million, while for the full year the figure should be three-digit. (Puls Biznesu, p.8) M.M.